title: Xuezhikang, an extract of cholestin, reduces cardiovascular events in type 2 diabetes patients with coronary heart disease: subgroup analysis of patients with type 2 diabetes from China coronary secondary prevention study (CCSPS).
abstract: Lipid-lowering therapy has been proven to reduce macrovascular complications of type 2 diabetes. Xuezhikang is an extract of cholestin and has a markedly modulating effect on lipids, but the effect of xuezhikang on reducing coronary events in diabetic patients with coronary heart disease (CHD) is less clear. A total of 591 diabetic patients with CHD were randomized to the xuezhikang group (n=306) and the placebo group (n=285). During the average 4 years of follow-up, there were 28 cases of CHD events (9.2%) in the xuezhikang group and 53 cases (18.6%) in the placebo group. Risk reduction for CHD events was 50.8% (P<0.001) by xuezhikang treatment. Xuezhikang decreased the risk of non-fatal MI by 63.8%, fatal MI by 58.5%, CHD sudden death by 26.9%, and other CHD death by 53.4%. CHD death totaled to 21 cases in the xuezhikang group (6.9%) and 35 cases in the placebo group (12.3%), indicating that xuezhikang significantly decreased the risk of CHD death by 44.1% (P<0.05). Seventy-two patients died from various causes, among which there were 27 patients in the xuezhikang group and 45 patients in the placebo group. The risk for all-cause death was 44.1% lower in the xuezhikang group than in the placebo group (P<0.01). This investigation demonstrates that xuezhikang therapy can be effective on reduction of cardiovascular events in diabetic patients with CHD with a reliable safety.
authors.affiliation: Department of Cardiology, The Second Xiangya Hospital, Central South University, ChangSha, China.
authors.forename: Shui-ping
authors.initials: SP
authors.lastname: Zhao
authors.forename: Zong-liang
authors.initials: ZL
authors.lastname: Lu
authors.forename: Bao-min
authors.initials: BM
authors.lastname: Du
authors.forename: Zuo
authors.initials: Z
authors.lastname: Chen
authors.forename: Yang-feng
authors.initials: YF
authors.lastname: Wu
authors.forename: Xue-hai
authors.initials: XH
authors.lastname: Yu
authors.forename: Yu-cheng
authors.initials: YC
authors.lastname: Zhao
authors.forename: Ling
authors.initials: L
authors.lastname: Liu
authors.forename: Hui-jun
authors.initials: HJ
authors.lastname: Ye
authors.forename: Zhi-hong
authors.initials: ZH
authors.lastname: Wu
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001688:Biological Products / Q000737:chemistry*; D002681:China / Q000453:epidemiology; D003327:Coronary Disease / Q000188:drug therapy* / Q000401:mortality; D003924:Diabetes Mellitus, Type 2 / Q000401:mortality*; D003925:Diabetic Angiopathies / Q000188:drug therapy* / Q000401:mortality; D004311:Double-Blind Method; D004365:Drugs, Chinese Herbal / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008055:Lipids / Q000097:blood; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy / Q000503:physiopathology
chemical_list: D001688:Biological Products; D004365:Drugs, Chinese Herbal; D008055:Lipids; C117343:red yeast rice; C496822:xuezhikang